Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-995-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees23
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions
What is Aileron Therapeutics' stock symbol?
Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How were Aileron Therapeutics' earnings last quarter?
Aileron Therapeutics Inc (NASDAQ:ALRN) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.13. View Aileron Therapeutics' Earnings History.
When is Aileron Therapeutics' next earnings date?
What price target have analysts set for ALRN?
3 equities research analysts have issued twelve-month price targets for Aileron Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they expect Aileron Therapeutics' share price to reach $6.00 in the next year. This suggests a possible upside of 383.9% from the stock's current price. View Analyst Price Targets for Aileron Therapeutics.
What is the consensus analysts' recommendation for Aileron Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aileron Therapeutics.
Has Aileron Therapeutics been receiving favorable news coverage?
Media coverage about ALRN stock has trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aileron Therapeutics earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of Aileron Therapeutics' key competitors?
Some companies that are related to Aileron Therapeutics include Nemus Bioscience (NMUS), Aravive (ARAV), Elite Pharmaceuticals (ELTP), Ovid Therapeutics (OVID), Medicure (MCUJF), Arcturus Therapeutics (ARCT), Acasti Pharma (ACST), IMMUTEP LTD/S (IMMP), Relmada Therapeutics (RLMD), Scpharmaceuticals (SCPH), Alimera Sciences (ALIM), Aquinox Pharmaceuticals (AQXP), Eyenovia (EYEN), Agile Therapeutics (AGRX) and NewLink Genetics (NLNK).
What other stocks do shareholders of Aileron Therapeutics own?
Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the folowing people:
- Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
- Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)
- Mr. Richard J. Wanstall, VP of Fin. & Operations
- Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)
- Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52)
When did Aileron Therapeutics IPO?
(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who are Aileron Therapeutics' major shareholders?
Aileron Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (13.72%), Morgan Stanley (2.68%), Renaissance Technologies LLC (0.96%), Blair William & Co. IL (0.15%) and Brave Asset Management Inc. (0.11%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Bioventures Ltd Novartis, Cvf, Llc, Donald Dougherty, John P Phd Longenecker, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Institutional Ownership Trends for Aileron Therapeutics.
Which major investors are selling Aileron Therapeutics stock?
ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Brave Asset Management Inc.. Company insiders that have sold Aileron Therapeutics company stock in the last year include Apple Tree Partners Ii Lp and Bioventures Ltd Novartis. View Insider Buying and Selling for Aileron Therapeutics.
Which major investors are buying Aileron Therapeutics stock?
ALRN stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Blair William & Co. IL and Morgan Stanley. Company insiders that have bought Aileron Therapeutics stock in the last two years include Cvf, Llc, Donald Dougherty, John P Phd Longenecker, Lilly Ventures Fund I Llc, Manuel Aivado and Reinhard J Ambros. View Insider Buying and Selling for Aileron Therapeutics.
How do I buy shares of Aileron Therapeutics?
Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aileron Therapeutics' stock price today?
One share of ALRN stock can currently be purchased for approximately $1.24.
How big of a company is Aileron Therapeutics?
Aileron Therapeutics has a market capitalization of $18.45 million. Aileron Therapeutics employs 23 workers across the globe.
What is Aileron Therapeutics' official website?
How can I contact Aileron Therapeutics?
Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]
MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
